nodes	percent_of_prediction	percent_of_DWPC	metapath
Sunitinib—pancreatic cancer—liver cancer	0.2	0.544	CtDrD
Sunitinib—kidney cancer—liver cancer	0.167	0.456	CtDrD
Sunitinib—KDR—liver cancer	0.101	1	CbGaD
Sunitinib—HIPK3—Sorafenib—liver cancer	0.0414	0.12	CbGbCtD
Sunitinib—FLT1—Sorafenib—liver cancer	0.0238	0.0692	CbGbCtD
Sunitinib—MAP3K7—Sorafenib—liver cancer	0.0238	0.0692	CbGbCtD
Sunitinib—AURKC—Sorafenib—liver cancer	0.0238	0.0692	CbGbCtD
Sunitinib—FLT4—Sorafenib—liver cancer	0.0199	0.0578	CbGbCtD
Sunitinib—FGFR1—Sorafenib—liver cancer	0.0199	0.0578	CbGbCtD
Sunitinib—FLT3—Sorafenib—liver cancer	0.0172	0.05	CbGbCtD
Sunitinib—RET—Sorafenib—liver cancer	0.0172	0.05	CbGbCtD
Sunitinib—KDR—Sorafenib—liver cancer	0.0172	0.05	CbGbCtD
Sunitinib—HIPK4—Sorafenib—liver cancer	0.0152	0.0442	CbGbCtD
Sunitinib—EPHB6—Sorafenib—liver cancer	0.0152	0.0442	CbGbCtD
Sunitinib—STK10—Sorafenib—liver cancer	0.0137	0.0397	CbGbCtD
Sunitinib—CSF1R—Sorafenib—liver cancer	0.0137	0.0397	CbGbCtD
Sunitinib—PDGFRA—Sorafenib—liver cancer	0.0137	0.0397	CbGbCtD
Sunitinib—KIT—Sorafenib—liver cancer	0.0137	0.0397	CbGbCtD
Sunitinib—MAP2K5—Sorafenib—liver cancer	0.0124	0.0361	CbGbCtD
Sunitinib—PDGFRB—Sorafenib—liver cancer	0.0124	0.0361	CbGbCtD
Sunitinib—MAP3K19—Sorafenib—liver cancer	0.0114	0.0332	CbGbCtD
Sunitinib—ABCC4—Sorafenib—liver cancer	0.00419	0.0122	CbGbCtD
Sunitinib—ABCC2—bile canaliculus—liver cancer	0.00329	0.101	CbGeAlD
Sunitinib—ABCC2—Sorafenib—liver cancer	0.00249	0.00725	CbGbCtD
Sunitinib—ABCG2—Sorafenib—liver cancer	0.00225	0.00656	CbGbCtD
Sunitinib—MYLK—umbilical vein—liver cancer	0.0017	0.052	CbGeAlD
Sunitinib—CYP3A7—Sorafenib—liver cancer	0.00166	0.00484	CbGbCtD
Sunitinib—CYP3A7-CYP3A51P—Sorafenib—liver cancer	0.00166	0.00484	CbGbCtD
Sunitinib—ABCC2—Doxorubicin—liver cancer	0.00151	0.0044	CbGbCtD
Sunitinib—ABCG2—Doxorubicin—liver cancer	0.00137	0.00398	CbGbCtD
Sunitinib—CYP3A5—Sorafenib—liver cancer	0.00125	0.00363	CbGbCtD
Sunitinib—ABCC2—bile duct—liver cancer	0.00103	0.0315	CbGeAlD
Sunitinib—FLT1—umbilical vein—liver cancer	0.000946	0.029	CbGeAlD
Sunitinib—ABCB1—Sorafenib—liver cancer	0.000813	0.00236	CbGbCtD
Sunitinib—KDR—umbilical vein—liver cancer	0.0008	0.0245	CbGeAlD
Sunitinib—ABCC2—bile—liver cancer	0.00079	0.0242	CbGeAlD
Sunitinib—MYLK—gall bladder—liver cancer	0.000698	0.0214	CbGeAlD
Sunitinib—ABCB1—Doxorubicin—liver cancer	0.000493	0.00143	CbGbCtD
Sunitinib—OXSR1—embryo—liver cancer	0.00049	0.015	CbGeAlD
Sunitinib—CYP3A4—Sorafenib—liver cancer	0.000487	0.00142	CbGbCtD
Sunitinib—RPS6KA2—embryo—liver cancer	0.000482	0.0148	CbGeAlD
Sunitinib—MYLK—embryo—liver cancer	0.000443	0.0136	CbGeAlD
Sunitinib—ALK—embryo—liver cancer	0.000411	0.0126	CbGeAlD
Sunitinib—TLK2—liver—liver cancer	0.000398	0.0122	CbGeAlD
Sunitinib—ROCK1—embryo—liver cancer	0.000379	0.0116	CbGeAlD
Sunitinib—PDGFRA—gall bladder—liver cancer	0.000365	0.0112	CbGeAlD
Sunitinib—RPS6KA3—embryo—liver cancer	0.000344	0.0106	CbGeAlD
Sunitinib—MAP2K1—embryo—liver cancer	0.000342	0.0105	CbGeAlD
Sunitinib—ERN1—liver—liver cancer	0.000324	0.00993	CbGeAlD
Sunitinib—PTK2B—embryo—liver cancer	0.000318	0.00974	CbGeAlD
Sunitinib—FLT4—embryo—liver cancer	0.000317	0.00972	CbGeAlD
Sunitinib—STK17B—liver—liver cancer	0.000312	0.00956	CbGeAlD
Sunitinib—CYP3A4—Doxorubicin—liver cancer	0.000295	0.00086	CbGbCtD
Sunitinib—KIT—gall bladder—liver cancer	0.000291	0.00893	CbGeAlD
Sunitinib—STK17A—liver—liver cancer	0.000287	0.0088	CbGeAlD
Sunitinib—PDGFRB—gall bladder—liver cancer	0.000285	0.00872	CbGeAlD
Sunitinib—CDK14—liver—liver cancer	0.000283	0.00868	CbGeAlD
Sunitinib—RPS6KB1—embryo—liver cancer	0.000282	0.00863	CbGeAlD
Sunitinib—RET—embryo—liver cancer	0.00028	0.00858	CbGeAlD
Sunitinib—FGR—embryo—liver cancer	0.00028	0.00858	CbGeAlD
Sunitinib—CDK16—liver—liver cancer	0.000279	0.00856	CbGeAlD
Sunitinib—LATS2—liver—liver cancer	0.000279	0.00856	CbGeAlD
Sunitinib—FGFR2—embryo—liver cancer	0.000266	0.00815	CbGeAlD
Sunitinib—CLK4—liver—liver cancer	0.000265	0.00813	CbGeAlD
Sunitinib—JAK2—embryo—liver cancer	0.000265	0.00811	CbGeAlD
Sunitinib—FYN—embryo—liver cancer	0.000261	0.008	CbGeAlD
Sunitinib—DAPK1—liver—liver cancer	0.000256	0.00785	CbGeAlD
Sunitinib—STK11—liver—liver cancer	0.000248	0.0076	CbGeAlD
Sunitinib—BRD4—liver—liver cancer	0.000248	0.0076	CbGeAlD
Sunitinib—FLT1—embryo—liver cancer	0.000247	0.00756	CbGeAlD
Sunitinib—RPS6KA1—liver—liver cancer	0.000246	0.00752	CbGeAlD
Sunitinib—RIOK1—liver—liver cancer	0.000246	0.00752	CbGeAlD
Sunitinib—TNIK—liver—liver cancer	0.000241	0.00738	CbGeAlD
Sunitinib—SGK3—liver—liver cancer	0.000239	0.00731	CbGeAlD
Sunitinib—ICK—liver—liver cancer	0.000236	0.00724	CbGeAlD
Sunitinib—PDGFRA—embryo—liver cancer	0.000231	0.00708	CbGeAlD
Sunitinib—NUAK1—liver—liver cancer	0.000228	0.00699	CbGeAlD
Sunitinib—OXSR1—liver—liver cancer	0.000226	0.00694	CbGeAlD
Sunitinib—SNRK—liver—liver cancer	0.000226	0.00694	CbGeAlD
Sunitinib—INSR—liver—liver cancer	0.000226	0.00694	CbGeAlD
Sunitinib—STK38—liver—liver cancer	0.000223	0.00683	CbGeAlD
Sunitinib—RPS6KA2—liver—liver cancer	0.000223	0.00683	CbGeAlD
Sunitinib—CSNK1G2—liver—liver cancer	0.000219	0.00672	CbGeAlD
Sunitinib—PKN1—liver—liver cancer	0.000219	0.00672	CbGeAlD
Sunitinib—PRPF4—liver—liver cancer	0.000216	0.00662	CbGeAlD
Sunitinib—PRPF4B—liver—liver cancer	0.000213	0.00653	CbGeAlD
Sunitinib—KDR—embryo—liver cancer	0.000209	0.00639	CbGeAlD
Sunitinib—CSNK2A1—liver—liver cancer	0.000207	0.00635	CbGeAlD
Sunitinib—MYLK—liver—liver cancer	0.000205	0.00627	CbGeAlD
Sunitinib—CSF1R—embryo—liver cancer	0.000203	0.00623	CbGeAlD
Sunitinib—STK4—liver—liver cancer	0.000201	0.00616	CbGeAlD
Sunitinib—PHKG2—liver—liver cancer	0.000197	0.00605	CbGeAlD
Sunitinib—STK24—liver—liver cancer	0.000196	0.00601	CbGeAlD
Sunitinib—STK16—liver—liver cancer	0.000191	0.00585	CbGeAlD
Sunitinib—HIPK2—liver—liver cancer	0.00019	0.00582	CbGeAlD
Sunitinib—HIPK3—liver—liver cancer	0.00019	0.00582	CbGeAlD
Sunitinib—RIOK2—liver—liver cancer	0.000188	0.00576	CbGeAlD
Sunitinib—TNK1—liver—liver cancer	0.000188	0.00576	CbGeAlD
Sunitinib—KIT—embryo—liver cancer	0.000185	0.00566	CbGeAlD
Sunitinib—DAPK3—liver—liver cancer	0.000183	0.00559	CbGeAlD
Sunitinib—CLK2—liver—liver cancer	0.000181	0.00554	CbGeAlD
Sunitinib—PDGFRB—embryo—liver cancer	0.00018	0.00553	CbGeAlD
Sunitinib—MAP4K2—liver—liver cancer	0.00018	0.00551	CbGeAlD
Sunitinib—STK3—liver—liver cancer	0.000178	0.00544	CbGeAlD
Sunitinib—ROCK1—liver—liver cancer	0.000175	0.00537	CbGeAlD
Sunitinib—DYRK1A—liver—liver cancer	0.000171	0.00524	CbGeAlD
Sunitinib—MERTK—liver—liver cancer	0.000167	0.00511	CbGeAlD
Sunitinib—MAP4K4—liver—liver cancer	0.000164	0.00502	CbGeAlD
Sunitinib—NUAK2—liver—liver cancer	0.000163	0.00498	CbGeAlD
Sunitinib—FLT3—liver—liver cancer	0.000162	0.00495	CbGeAlD
Sunitinib—MAP3K12—liver—liver cancer	0.000162	0.00495	CbGeAlD
Sunitinib—RPS6KA3—liver—liver cancer	0.000159	0.00488	CbGeAlD
Sunitinib—MAP2K1—liver—liver cancer	0.000158	0.00485	CbGeAlD
Sunitinib—CSNK1A1—liver—liver cancer	0.000156	0.00478	CbGeAlD
Sunitinib—CLK1—liver—liver cancer	0.000155	0.00475	CbGeAlD
Sunitinib—CAMK2G—liver—liver cancer	0.000152	0.00467	CbGeAlD
Sunitinib—BMP2K—liver—liver cancer	0.000152	0.00467	CbGeAlD
Sunitinib—LRRK2—liver—liver cancer	0.000151	0.00462	CbGeAlD
Sunitinib—PRKAA1—liver—liver cancer	0.000149	0.00456	CbGeAlD
Sunitinib—PTK2B—liver—liver cancer	0.000147	0.00451	CbGeAlD
Sunitinib—FLT4—liver—liver cancer	0.000147	0.00449	CbGeAlD
Sunitinib—CSNK1E—liver—liver cancer	0.000145	0.00443	CbGeAlD
Sunitinib—FGFR1—liver—liver cancer	0.000145	0.00443	CbGeAlD
Sunitinib—IRAK4—liver—liver cancer	0.000142	0.00436	CbGeAlD
Sunitinib—ULK3—liver—liver cancer	0.000139	0.00427	CbGeAlD
Sunitinib—MAP2K2—liver—liver cancer	0.000139	0.00427	CbGeAlD
Sunitinib—MAP3K2—liver—liver cancer	0.000138	0.00424	CbGeAlD
Sunitinib—MAP3K7—liver—liver cancer	0.000137	0.0042	CbGeAlD
Sunitinib—TBK1—liver—liver cancer	0.000135	0.00415	CbGeAlD
Sunitinib—TYK2—liver—liver cancer	0.000135	0.00412	CbGeAlD
Sunitinib—IRAK1—liver—liver cancer	0.000133	0.00407	CbGeAlD
Sunitinib—RPS6KB1—liver—liver cancer	0.00013	0.00399	CbGeAlD
Sunitinib—FGR—liver—liver cancer	0.00013	0.00397	CbGeAlD
Sunitinib—AXL—liver—liver cancer	0.000129	0.00395	CbGeAlD
Sunitinib—SLK—liver—liver cancer	0.000124	0.0038	CbGeAlD
Sunitinib—CYP3A7—liver—liver cancer	0.000124	0.00379	CbGeAlD
Sunitinib—FGFR2—liver—liver cancer	0.000123	0.00377	CbGeAlD
Sunitinib—JAK2—liver—liver cancer	0.000122	0.00375	CbGeAlD
Sunitinib—FYN—liver—liver cancer	0.000121	0.0037	CbGeAlD
Sunitinib—DYRK1A—Doxorubicin—Epirubicin—liver cancer	0.000118	0.0776	CbGdCrCtD
Sunitinib—DYRK1A—Idarubicin—Epirubicin—liver cancer	0.000118	0.0776	CbGdCrCtD
Sunitinib—DYRK1A—Daunorubicin—Epirubicin—liver cancer	0.000118	0.0776	CbGdCrCtD
Sunitinib—MAP3K3—liver—liver cancer	0.000118	0.00361	CbGeAlD
Sunitinib—MAP4K5—liver—liver cancer	0.000118	0.00361	CbGeAlD
Sunitinib—FLT1—liver—liver cancer	0.000114	0.00349	CbGeAlD
Sunitinib—DYRK1A—Epirubicin—Doxorubicin—liver cancer	0.000109	0.0718	CbGdCrCtD
Sunitinib—DYRK1A—Idarubicin—Doxorubicin—liver cancer	0.000109	0.0718	CbGdCrCtD
Sunitinib—DYRK1A—Daunorubicin—Doxorubicin—liver cancer	0.000109	0.0718	CbGdCrCtD
Sunitinib—YES1—liver—liver cancer	0.000109	0.00334	CbGeAlD
Sunitinib—STK10—liver—liver cancer	0.000108	0.00331	CbGeAlD
Sunitinib—TAOK3—liver—liver cancer	0.000108	0.0033	CbGeAlD
Sunitinib—PDGFRA—liver—liver cancer	0.000107	0.00327	CbGeAlD
Sunitinib—CYP3A7-CYP3A51P—liver—liver cancer	0.000105	0.00322	CbGeAlD
Sunitinib—PRPF4—Daunorubicin—Epirubicin—liver cancer	0.000102	0.067	CbGdCrCtD
Sunitinib—PRPF4—Idarubicin—Epirubicin—liver cancer	0.000102	0.067	CbGdCrCtD
Sunitinib—KDR—liver—liver cancer	9.64e-05	0.00295	CbGeAlD
Sunitinib—MAP2K5—liver—liver cancer	9.64e-05	0.00295	CbGeAlD
Sunitinib—PRPF4—Idarubicin—Doxorubicin—liver cancer	9.43e-05	0.062	CbGdCrCtD
Sunitinib—PRPF4—Daunorubicin—Doxorubicin—liver cancer	9.43e-05	0.062	CbGdCrCtD
Sunitinib—CSF1R—liver—liver cancer	9.41e-05	0.00288	CbGeAlD
Sunitinib—KIT—liver—liver cancer	8.55e-05	0.00262	CbGeAlD
Sunitinib—PDGFRB—liver—liver cancer	8.35e-05	0.00256	CbGeAlD
Sunitinib—PLK4—Idarubicin—Epirubicin—liver cancer	8.06e-05	0.053	CbGdCrCtD
Sunitinib—PLK4—Doxorubicin—Epirubicin—liver cancer	8.06e-05	0.053	CbGdCrCtD
Sunitinib—PLK4—Idarubicin—Doxorubicin—liver cancer	7.46e-05	0.049	CbGdCrCtD
Sunitinib—PLK4—Epirubicin—Doxorubicin—liver cancer	7.46e-05	0.049	CbGdCrCtD
Sunitinib—CHEK2—Doxorubicin—Epirubicin—liver cancer	7.1e-05	0.0467	CbGdCrCtD
Sunitinib—Dyspnoea—Sorafenib—liver cancer	7.1e-05	0.00115	CcSEcCtD
Sunitinib—Dyspepsia—Sorafenib—liver cancer	7.01e-05	0.00113	CcSEcCtD
Sunitinib—Oesophagitis—Doxorubicin—liver cancer	6.97e-05	0.00113	CcSEcCtD
Sunitinib—Rash maculo-papular—Doxorubicin—liver cancer	6.94e-05	0.00112	CcSEcCtD
Sunitinib—Decreased appetite—Sorafenib—liver cancer	6.92e-05	0.00112	CcSEcCtD
Sunitinib—Mouth ulceration—Doxorubicin—liver cancer	6.9e-05	0.00112	CcSEcCtD
Sunitinib—Neoplasm—Doxorubicin—liver cancer	6.9e-05	0.00112	CcSEcCtD
Sunitinib—Blood alkaline phosphatase increased—Epirubicin—liver cancer	6.88e-05	0.00111	CcSEcCtD
Sunitinib—Gastrointestinal disorder—Sorafenib—liver cancer	6.87e-05	0.00111	CcSEcCtD
Sunitinib—Fatigue—Sorafenib—liver cancer	6.86e-05	0.00111	CcSEcCtD
Sunitinib—Hepatic function abnormal—Epirubicin—liver cancer	6.85e-05	0.00111	CcSEcCtD
Sunitinib—Pain—Sorafenib—liver cancer	6.81e-05	0.0011	CcSEcCtD
Sunitinib—Constipation—Sorafenib—liver cancer	6.81e-05	0.0011	CcSEcCtD
Sunitinib—Pulmonary oedema—Doxorubicin—liver cancer	6.79e-05	0.0011	CcSEcCtD
Sunitinib—Hepatic failure—Epirubicin—liver cancer	6.66e-05	0.00108	CcSEcCtD
Sunitinib—Eczema—Epirubicin—liver cancer	6.66e-05	0.00108	CcSEcCtD
Sunitinib—ABCC4—liver—liver cancer	6.65e-05	0.00204	CbGeAlD
Sunitinib—Sepsis—Doxorubicin—liver cancer	6.62e-05	0.00107	CcSEcCtD
Sunitinib—Cardiac failure congestive—Epirubicin—liver cancer	6.6e-05	0.00107	CcSEcCtD
Sunitinib—CHEK2—Epirubicin—Doxorubicin—liver cancer	6.57e-05	0.0432	CbGdCrCtD
Sunitinib—Gastrointestinal pain—Sorafenib—liver cancer	6.51e-05	0.00105	CcSEcCtD
Sunitinib—Renal failure acute—Epirubicin—liver cancer	6.49e-05	0.00105	CcSEcCtD
Sunitinib—ABCC2—liver—liver cancer	6.43e-05	0.00197	CbGeAlD
Sunitinib—Hot flush—Epirubicin—liver cancer	6.4e-05	0.00104	CcSEcCtD
Sunitinib—Blood alkaline phosphatase increased—Doxorubicin—liver cancer	6.37e-05	0.00103	CcSEcCtD
Sunitinib—Menopausal symptoms—Epirubicin—liver cancer	6.35e-05	0.00103	CcSEcCtD
Sunitinib—Hepatic function abnormal—Doxorubicin—liver cancer	6.34e-05	0.00103	CcSEcCtD
Sunitinib—Body temperature increased—Sorafenib—liver cancer	6.29e-05	0.00102	CcSEcCtD
Sunitinib—Abdominal pain—Sorafenib—liver cancer	6.29e-05	0.00102	CcSEcCtD
Sunitinib—Renal impairment—Epirubicin—liver cancer	6.29e-05	0.00102	CcSEcCtD
Sunitinib—Dermatitis bullous—Epirubicin—liver cancer	6.26e-05	0.00101	CcSEcCtD
Sunitinib—Eczema—Doxorubicin—liver cancer	6.16e-05	0.000998	CcSEcCtD
Sunitinib—Hepatic failure—Doxorubicin—liver cancer	6.16e-05	0.000998	CcSEcCtD
Sunitinib—Hypoglycaemia—Epirubicin—liver cancer	6.13e-05	0.000993	CcSEcCtD
Sunitinib—Cardiac failure—Epirubicin—liver cancer	6.13e-05	0.000993	CcSEcCtD
Sunitinib—Cerebrovascular accident—Epirubicin—liver cancer	6.11e-05	0.000989	CcSEcCtD
Sunitinib—Cardiac failure congestive—Doxorubicin—liver cancer	6.11e-05	0.000989	CcSEcCtD
Sunitinib—Hyponatraemia—Epirubicin—liver cancer	6.01e-05	0.000973	CcSEcCtD
Sunitinib—Renal failure acute—Doxorubicin—liver cancer	6e-05	0.000971	CcSEcCtD
Sunitinib—Pain in extremity—Epirubicin—liver cancer	5.99e-05	0.000969	CcSEcCtD
Sunitinib—Hot flush—Doxorubicin—liver cancer	5.92e-05	0.000959	CcSEcCtD
Sunitinib—Menopausal symptoms—Doxorubicin—liver cancer	5.87e-05	0.00095	CcSEcCtD
Sunitinib—Hypersensitivity—Sorafenib—liver cancer	5.87e-05	0.00095	CcSEcCtD
Sunitinib—Renal impairment—Doxorubicin—liver cancer	5.82e-05	0.000942	CcSEcCtD
Sunitinib—Dermatitis bullous—Doxorubicin—liver cancer	5.8e-05	0.000938	CcSEcCtD
Sunitinib—Face oedema—Epirubicin—liver cancer	5.78e-05	0.000936	CcSEcCtD
Sunitinib—Asthenia—Sorafenib—liver cancer	5.71e-05	0.000925	CcSEcCtD
Sunitinib—Cardiac failure—Doxorubicin—liver cancer	5.68e-05	0.000919	CcSEcCtD
Sunitinib—Hypoglycaemia—Doxorubicin—liver cancer	5.68e-05	0.000919	CcSEcCtD
Sunitinib—Cerebrovascular accident—Doxorubicin—liver cancer	5.65e-05	0.000915	CcSEcCtD
Sunitinib—Pruritus—Sorafenib—liver cancer	5.63e-05	0.000912	CcSEcCtD
Sunitinib—Blood creatinine increased—Epirubicin—liver cancer	5.61e-05	0.000908	CcSEcCtD
Sunitinib—Dehydration—Epirubicin—liver cancer	5.57e-05	0.000901	CcSEcCtD
Sunitinib—Hyponatraemia—Doxorubicin—liver cancer	5.56e-05	0.0009	CcSEcCtD
Sunitinib—Pain in extremity—Doxorubicin—liver cancer	5.54e-05	0.000897	CcSEcCtD
Sunitinib—Liver function test abnormal—Epirubicin—liver cancer	5.53e-05	0.000895	CcSEcCtD
Sunitinib—Dry skin—Epirubicin—liver cancer	5.49e-05	0.000888	CcSEcCtD
Sunitinib—Abdominal pain upper—Epirubicin—liver cancer	5.47e-05	0.000885	CcSEcCtD
Sunitinib—Hypokalaemia—Epirubicin—liver cancer	5.45e-05	0.000882	CcSEcCtD
Sunitinib—Diarrhoea—Sorafenib—liver cancer	5.45e-05	0.000882	CcSEcCtD
Sunitinib—Toxic epidermal necrolysis—Epirubicin—liver cancer	5.39e-05	0.000873	CcSEcCtD
Sunitinib—Aspartate aminotransferase increased—Epirubicin—liver cancer	5.39e-05	0.000873	CcSEcCtD
Sunitinib—Nasopharyngitis—Epirubicin—liver cancer	5.35e-05	0.000867	CcSEcCtD
Sunitinib—Face oedema—Doxorubicin—liver cancer	5.35e-05	0.000866	CcSEcCtD
Sunitinib—Muscular weakness—Epirubicin—liver cancer	5.28e-05	0.000855	CcSEcCtD
Sunitinib—Alanine aminotransferase increased—Epirubicin—liver cancer	5.28e-05	0.000855	CcSEcCtD
Sunitinib—Dizziness—Sorafenib—liver cancer	5.27e-05	0.000852	CcSEcCtD
Sunitinib—Abdominal distension—Epirubicin—liver cancer	5.21e-05	0.000843	CcSEcCtD
Sunitinib—Blood creatinine increased—Doxorubicin—liver cancer	5.19e-05	0.00084	CcSEcCtD
Sunitinib—Dysphagia—Epirubicin—liver cancer	5.17e-05	0.000838	CcSEcCtD
Sunitinib—Dehydration—Doxorubicin—liver cancer	5.15e-05	0.000834	CcSEcCtD
Sunitinib—Liver function test abnormal—Doxorubicin—liver cancer	5.11e-05	0.000828	CcSEcCtD
Sunitinib—Dry skin—Doxorubicin—liver cancer	5.08e-05	0.000822	CcSEcCtD
Sunitinib—Pancreatitis—Epirubicin—liver cancer	5.07e-05	0.000821	CcSEcCtD
Sunitinib—Vomiting—Sorafenib—liver cancer	5.06e-05	0.00082	CcSEcCtD
Sunitinib—Abdominal pain upper—Doxorubicin—liver cancer	5.06e-05	0.000819	CcSEcCtD
Sunitinib—Hypokalaemia—Doxorubicin—liver cancer	5.04e-05	0.000816	CcSEcCtD
Sunitinib—Rash—Sorafenib—liver cancer	5.02e-05	0.000813	CcSEcCtD
Sunitinib—Dermatitis—Sorafenib—liver cancer	5.02e-05	0.000812	CcSEcCtD
Sunitinib—ABCB1—embryo—liver cancer	5e-05	0.00153	CbGeAlD
Sunitinib—Toxic epidermal necrolysis—Doxorubicin—liver cancer	4.99e-05	0.000808	CcSEcCtD
Sunitinib—Aspartate aminotransferase increased—Doxorubicin—liver cancer	4.99e-05	0.000808	CcSEcCtD
Sunitinib—Headache—Sorafenib—liver cancer	4.99e-05	0.000808	CcSEcCtD
Sunitinib—Bronchitis—Epirubicin—liver cancer	4.98e-05	0.000806	CcSEcCtD
Sunitinib—Nasopharyngitis—Doxorubicin—liver cancer	4.95e-05	0.000802	CcSEcCtD
Sunitinib—Pancytopenia—Epirubicin—liver cancer	4.91e-05	0.000796	CcSEcCtD
Sunitinib—Muscular weakness—Doxorubicin—liver cancer	4.89e-05	0.000791	CcSEcCtD
Sunitinib—Alanine aminotransferase increased—Doxorubicin—liver cancer	4.89e-05	0.000791	CcSEcCtD
Sunitinib—Neutropenia—Epirubicin—liver cancer	4.84e-05	0.000783	CcSEcCtD
Sunitinib—Abdominal distension—Doxorubicin—liver cancer	4.82e-05	0.00078	CcSEcCtD
Sunitinib—Upper respiratory tract infection—Epirubicin—liver cancer	4.81e-05	0.000779	CcSEcCtD
Sunitinib—Dysphagia—Doxorubicin—liver cancer	4.79e-05	0.000775	CcSEcCtD
Sunitinib—Nausea—Sorafenib—liver cancer	4.73e-05	0.000766	CcSEcCtD
Sunitinib—Pancreatitis—Doxorubicin—liver cancer	4.69e-05	0.00076	CcSEcCtD
Sunitinib—ABCG2—liver—liver cancer	4.69e-05	0.00144	CbGeAlD
Sunitinib—Weight decreased—Epirubicin—liver cancer	4.68e-05	0.000758	CcSEcCtD
Sunitinib—Hyperglycaemia—Epirubicin—liver cancer	4.67e-05	0.000756	CcSEcCtD
Sunitinib—Pneumonia—Epirubicin—liver cancer	4.64e-05	0.000751	CcSEcCtD
Sunitinib—Infestation—Epirubicin—liver cancer	4.61e-05	0.000747	CcSEcCtD
Sunitinib—Infestation NOS—Epirubicin—liver cancer	4.61e-05	0.000747	CcSEcCtD
Sunitinib—Bronchitis—Doxorubicin—liver cancer	4.6e-05	0.000745	CcSEcCtD
Sunitinib—Stevens-Johnson syndrome—Epirubicin—liver cancer	4.57e-05	0.000741	CcSEcCtD
Sunitinib—Pancytopenia—Doxorubicin—liver cancer	4.55e-05	0.000736	CcSEcCtD
Sunitinib—Renal failure—Epirubicin—liver cancer	4.54e-05	0.000734	CcSEcCtD
Sunitinib—Neuropathy peripheral—Epirubicin—liver cancer	4.52e-05	0.000732	CcSEcCtD
Sunitinib—Stomatitis—Epirubicin—liver cancer	4.5e-05	0.000728	CcSEcCtD
Sunitinib—Urinary tract infection—Epirubicin—liver cancer	4.48e-05	0.000726	CcSEcCtD
Sunitinib—Neutropenia—Doxorubicin—liver cancer	4.48e-05	0.000725	CcSEcCtD
Sunitinib—Upper respiratory tract infection—Doxorubicin—liver cancer	4.45e-05	0.00072	CcSEcCtD
Sunitinib—Hepatobiliary disease—Epirubicin—liver cancer	4.36e-05	0.000706	CcSEcCtD
Sunitinib—CYP3A5—liver—liver cancer	4.35e-05	0.00133	CbGeAlD
Sunitinib—Epistaxis—Epirubicin—liver cancer	4.35e-05	0.000705	CcSEcCtD
Sunitinib—Weight decreased—Doxorubicin—liver cancer	4.33e-05	0.000701	CcSEcCtD
Sunitinib—Hyperglycaemia—Doxorubicin—liver cancer	4.32e-05	0.000699	CcSEcCtD
Sunitinib—Pneumonia—Doxorubicin—liver cancer	4.29e-05	0.000695	CcSEcCtD
Sunitinib—Infestation NOS—Doxorubicin—liver cancer	4.27e-05	0.000691	CcSEcCtD
Sunitinib—Infestation—Doxorubicin—liver cancer	4.27e-05	0.000691	CcSEcCtD
Sunitinib—Stevens-Johnson syndrome—Doxorubicin—liver cancer	4.23e-05	0.000685	CcSEcCtD
Sunitinib—Bradycardia—Epirubicin—liver cancer	4.22e-05	0.000683	CcSEcCtD
Sunitinib—Renal failure—Doxorubicin—liver cancer	4.2e-05	0.000679	CcSEcCtD
Sunitinib—Neuropathy peripheral—Doxorubicin—liver cancer	4.18e-05	0.000677	CcSEcCtD
Sunitinib—Haemoglobin—Epirubicin—liver cancer	4.16e-05	0.000674	CcSEcCtD
Sunitinib—Stomatitis—Doxorubicin—liver cancer	4.16e-05	0.000674	CcSEcCtD
Sunitinib—Urinary tract infection—Doxorubicin—liver cancer	4.15e-05	0.000672	CcSEcCtD
Sunitinib—Haemorrhage—Epirubicin—liver cancer	4.14e-05	0.000671	CcSEcCtD
Sunitinib—Hepatitis—Epirubicin—liver cancer	4.14e-05	0.000671	CcSEcCtD
Sunitinib—Hypoaesthesia—Epirubicin—liver cancer	4.12e-05	0.000667	CcSEcCtD
Sunitinib—Urinary tract disorder—Epirubicin—liver cancer	4.09e-05	0.000662	CcSEcCtD
Sunitinib—Oedema peripheral—Epirubicin—liver cancer	4.08e-05	0.000661	CcSEcCtD
Sunitinib—Connective tissue disorder—Epirubicin—liver cancer	4.07e-05	0.000659	CcSEcCtD
Sunitinib—Urethral disorder—Epirubicin—liver cancer	4.06e-05	0.000657	CcSEcCtD
Sunitinib—Hepatobiliary disease—Doxorubicin—liver cancer	4.04e-05	0.000654	CcSEcCtD
Sunitinib—Epistaxis—Doxorubicin—liver cancer	4.03e-05	0.000652	CcSEcCtD
Sunitinib—Erythema multiforme—Epirubicin—liver cancer	3.92e-05	0.000634	CcSEcCtD
Sunitinib—Bradycardia—Doxorubicin—liver cancer	3.9e-05	0.000632	CcSEcCtD
Sunitinib—Eye disorder—Epirubicin—liver cancer	3.87e-05	0.000627	CcSEcCtD
Sunitinib—Haemoglobin—Doxorubicin—liver cancer	3.85e-05	0.000624	CcSEcCtD
Sunitinib—Flushing—Epirubicin—liver cancer	3.84e-05	0.000622	CcSEcCtD
Sunitinib—Cardiac disorder—Epirubicin—liver cancer	3.84e-05	0.000622	CcSEcCtD
Sunitinib—Haemorrhage—Doxorubicin—liver cancer	3.83e-05	0.00062	CcSEcCtD
Sunitinib—Hepatitis—Doxorubicin—liver cancer	3.83e-05	0.00062	CcSEcCtD
Sunitinib—Hypoaesthesia—Doxorubicin—liver cancer	3.81e-05	0.000617	CcSEcCtD
Sunitinib—Urinary tract disorder—Doxorubicin—liver cancer	3.78e-05	0.000613	CcSEcCtD
Sunitinib—Oedema peripheral—Doxorubicin—liver cancer	3.78e-05	0.000611	CcSEcCtD
Sunitinib—Connective tissue disorder—Doxorubicin—liver cancer	3.77e-05	0.00061	CcSEcCtD
Sunitinib—Angiopathy—Epirubicin—liver cancer	3.76e-05	0.000608	CcSEcCtD
Sunitinib—Urethral disorder—Doxorubicin—liver cancer	3.76e-05	0.000608	CcSEcCtD
Sunitinib—Immune system disorder—Epirubicin—liver cancer	3.74e-05	0.000606	CcSEcCtD
Sunitinib—Mediastinal disorder—Epirubicin—liver cancer	3.73e-05	0.000604	CcSEcCtD
Sunitinib—Chills—Epirubicin—liver cancer	3.72e-05	0.000602	CcSEcCtD
Sunitinib—Arrhythmia—Epirubicin—liver cancer	3.7e-05	0.000599	CcSEcCtD
Sunitinib—Alopecia—Epirubicin—liver cancer	3.66e-05	0.000593	CcSEcCtD
Sunitinib—Mental disorder—Epirubicin—liver cancer	3.63e-05	0.000587	CcSEcCtD
Sunitinib—Erythema multiforme—Doxorubicin—liver cancer	3.62e-05	0.000587	CcSEcCtD
Sunitinib—Malnutrition—Epirubicin—liver cancer	3.61e-05	0.000584	CcSEcCtD
Sunitinib—Erythema—Epirubicin—liver cancer	3.61e-05	0.000584	CcSEcCtD
Sunitinib—Eye disorder—Doxorubicin—liver cancer	3.58e-05	0.00058	CcSEcCtD
Sunitinib—Flushing—Doxorubicin—liver cancer	3.56e-05	0.000576	CcSEcCtD
Sunitinib—Cardiac disorder—Doxorubicin—liver cancer	3.56e-05	0.000576	CcSEcCtD
Sunitinib—Flatulence—Epirubicin—liver cancer	3.55e-05	0.000575	CcSEcCtD
Sunitinib—Dysgeusia—Epirubicin—liver cancer	3.53e-05	0.000572	CcSEcCtD
Sunitinib—Back pain—Epirubicin—liver cancer	3.49e-05	0.000565	CcSEcCtD
Sunitinib—Angiopathy—Doxorubicin—liver cancer	3.48e-05	0.000563	CcSEcCtD
Sunitinib—Muscle spasms—Epirubicin—liver cancer	3.47e-05	0.000561	CcSEcCtD
Sunitinib—Immune system disorder—Doxorubicin—liver cancer	3.46e-05	0.00056	CcSEcCtD
Sunitinib—Mediastinal disorder—Doxorubicin—liver cancer	3.45e-05	0.000559	CcSEcCtD
Sunitinib—Chills—Doxorubicin—liver cancer	3.44e-05	0.000557	CcSEcCtD
Sunitinib—Arrhythmia—Doxorubicin—liver cancer	3.42e-05	0.000554	CcSEcCtD
Sunitinib—Alopecia—Doxorubicin—liver cancer	3.39e-05	0.000548	CcSEcCtD
Sunitinib—Mental disorder—Doxorubicin—liver cancer	3.36e-05	0.000544	CcSEcCtD
Sunitinib—Malnutrition—Doxorubicin—liver cancer	3.34e-05	0.00054	CcSEcCtD
Sunitinib—Erythema—Doxorubicin—liver cancer	3.34e-05	0.00054	CcSEcCtD
Sunitinib—Anaemia—Epirubicin—liver cancer	3.33e-05	0.000539	CcSEcCtD
Sunitinib—Flatulence—Doxorubicin—liver cancer	3.29e-05	0.000532	CcSEcCtD
Sunitinib—CYP3A4—liver—liver cancer	3.27e-05	0.001	CbGeAlD
Sunitinib—Dysgeusia—Doxorubicin—liver cancer	3.27e-05	0.000529	CcSEcCtD
Sunitinib—Leukopenia—Epirubicin—liver cancer	3.23e-05	0.000522	CcSEcCtD
Sunitinib—Back pain—Doxorubicin—liver cancer	3.23e-05	0.000522	CcSEcCtD
Sunitinib—Muscle spasms—Doxorubicin—liver cancer	3.21e-05	0.000519	CcSEcCtD
Sunitinib—Cough—Epirubicin—liver cancer	3.15e-05	0.000509	CcSEcCtD
Sunitinib—Convulsion—Epirubicin—liver cancer	3.12e-05	0.000506	CcSEcCtD
Sunitinib—Hypertension—Epirubicin—liver cancer	3.11e-05	0.000504	CcSEcCtD
Sunitinib—Anaemia—Doxorubicin—liver cancer	3.08e-05	0.000499	CcSEcCtD
Sunitinib—Arthralgia—Epirubicin—liver cancer	3.07e-05	0.000497	CcSEcCtD
Sunitinib—Myalgia—Epirubicin—liver cancer	3.07e-05	0.000497	CcSEcCtD
Sunitinib—Chest pain—Epirubicin—liver cancer	3.07e-05	0.000497	CcSEcCtD
Sunitinib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—liver cancer	3.05e-05	0.000494	CcSEcCtD
Sunitinib—Dry mouth—Epirubicin—liver cancer	3e-05	0.000486	CcSEcCtD
Sunitinib—Leukopenia—Doxorubicin—liver cancer	2.99e-05	0.000483	CcSEcCtD
Sunitinib—Oedema—Epirubicin—liver cancer	2.94e-05	0.000476	CcSEcCtD
Sunitinib—Infection—Epirubicin—liver cancer	2.92e-05	0.000473	CcSEcCtD
Sunitinib—Cough—Doxorubicin—liver cancer	2.91e-05	0.000471	CcSEcCtD
Sunitinib—Shock—Epirubicin—liver cancer	2.9e-05	0.000469	CcSEcCtD
Sunitinib—Convulsion—Doxorubicin—liver cancer	2.89e-05	0.000468	CcSEcCtD
Sunitinib—Nervous system disorder—Epirubicin—liver cancer	2.89e-05	0.000467	CcSEcCtD
Sunitinib—Thrombocytopenia—Epirubicin—liver cancer	2.88e-05	0.000466	CcSEcCtD
Sunitinib—Hypertension—Doxorubicin—liver cancer	2.88e-05	0.000466	CcSEcCtD
Sunitinib—Skin disorder—Epirubicin—liver cancer	2.86e-05	0.000463	CcSEcCtD
Sunitinib—Chest pain—Doxorubicin—liver cancer	2.84e-05	0.00046	CcSEcCtD
Sunitinib—Arthralgia—Doxorubicin—liver cancer	2.84e-05	0.00046	CcSEcCtD
Sunitinib—Myalgia—Doxorubicin—liver cancer	2.84e-05	0.00046	CcSEcCtD
Sunitinib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—liver cancer	2.82e-05	0.000457	CcSEcCtD
Sunitinib—Anorexia—Epirubicin—liver cancer	2.81e-05	0.000454	CcSEcCtD
Sunitinib—Dry mouth—Doxorubicin—liver cancer	2.78e-05	0.00045	CcSEcCtD
Sunitinib—Oedema—Doxorubicin—liver cancer	2.72e-05	0.000441	CcSEcCtD
Sunitinib—Infection—Doxorubicin—liver cancer	2.71e-05	0.000438	CcSEcCtD
Sunitinib—Musculoskeletal discomfort—Epirubicin—liver cancer	2.68e-05	0.000434	CcSEcCtD
Sunitinib—Shock—Doxorubicin—liver cancer	2.68e-05	0.000434	CcSEcCtD
Sunitinib—Nervous system disorder—Doxorubicin—liver cancer	2.67e-05	0.000432	CcSEcCtD
Sunitinib—Thrombocytopenia—Doxorubicin—liver cancer	2.67e-05	0.000432	CcSEcCtD
Sunitinib—Insomnia—Epirubicin—liver cancer	2.66e-05	0.000431	CcSEcCtD
Sunitinib—Skin disorder—Doxorubicin—liver cancer	2.64e-05	0.000428	CcSEcCtD
Sunitinib—Paraesthesia—Epirubicin—liver cancer	2.64e-05	0.000428	CcSEcCtD
Sunitinib—Dyspnoea—Epirubicin—liver cancer	2.62e-05	0.000425	CcSEcCtD
Sunitinib—Anorexia—Doxorubicin—liver cancer	2.6e-05	0.00042	CcSEcCtD
Sunitinib—Dyspepsia—Epirubicin—liver cancer	2.59e-05	0.000419	CcSEcCtD
Sunitinib—Decreased appetite—Epirubicin—liver cancer	2.56e-05	0.000414	CcSEcCtD
Sunitinib—Gastrointestinal disorder—Epirubicin—liver cancer	2.54e-05	0.000411	CcSEcCtD
Sunitinib—Fatigue—Epirubicin—liver cancer	2.54e-05	0.000411	CcSEcCtD
Sunitinib—Pain—Epirubicin—liver cancer	2.52e-05	0.000407	CcSEcCtD
Sunitinib—Constipation—Epirubicin—liver cancer	2.52e-05	0.000407	CcSEcCtD
Sunitinib—Musculoskeletal discomfort—Doxorubicin—liver cancer	2.48e-05	0.000402	CcSEcCtD
Sunitinib—Insomnia—Doxorubicin—liver cancer	2.46e-05	0.000399	CcSEcCtD
Sunitinib—Paraesthesia—Doxorubicin—liver cancer	2.44e-05	0.000396	CcSEcCtD
Sunitinib—Dyspnoea—Doxorubicin—liver cancer	2.43e-05	0.000393	CcSEcCtD
Sunitinib—Gastrointestinal pain—Epirubicin—liver cancer	2.41e-05	0.00039	CcSEcCtD
Sunitinib—Dyspepsia—Doxorubicin—liver cancer	2.4e-05	0.000388	CcSEcCtD
Sunitinib—Decreased appetite—Doxorubicin—liver cancer	2.37e-05	0.000383	CcSEcCtD
Sunitinib—Gastrointestinal disorder—Doxorubicin—liver cancer	2.35e-05	0.000381	CcSEcCtD
Sunitinib—Fatigue—Doxorubicin—liver cancer	2.35e-05	0.00038	CcSEcCtD
Sunitinib—Pain—Doxorubicin—liver cancer	2.33e-05	0.000377	CcSEcCtD
Sunitinib—Constipation—Doxorubicin—liver cancer	2.33e-05	0.000377	CcSEcCtD
Sunitinib—Abdominal pain—Epirubicin—liver cancer	2.33e-05	0.000377	CcSEcCtD
Sunitinib—Body temperature increased—Epirubicin—liver cancer	2.33e-05	0.000377	CcSEcCtD
Sunitinib—ABCB1—liver—liver cancer	2.31e-05	0.000709	CbGeAlD
Sunitinib—Gastrointestinal pain—Doxorubicin—liver cancer	2.23e-05	0.00036	CcSEcCtD
Sunitinib—Hypersensitivity—Epirubicin—liver cancer	2.17e-05	0.000351	CcSEcCtD
Sunitinib—Body temperature increased—Doxorubicin—liver cancer	2.15e-05	0.000348	CcSEcCtD
Sunitinib—Abdominal pain—Doxorubicin—liver cancer	2.15e-05	0.000348	CcSEcCtD
Sunitinib—Asthenia—Epirubicin—liver cancer	2.11e-05	0.000342	CcSEcCtD
Sunitinib—Pruritus—Epirubicin—liver cancer	2.08e-05	0.000337	CcSEcCtD
Sunitinib—Diarrhoea—Epirubicin—liver cancer	2.01e-05	0.000326	CcSEcCtD
Sunitinib—Hypersensitivity—Doxorubicin—liver cancer	2.01e-05	0.000325	CcSEcCtD
Sunitinib—Asthenia—Doxorubicin—liver cancer	1.95e-05	0.000316	CcSEcCtD
Sunitinib—Dizziness—Epirubicin—liver cancer	1.95e-05	0.000315	CcSEcCtD
Sunitinib—Pruritus—Doxorubicin—liver cancer	1.93e-05	0.000312	CcSEcCtD
Sunitinib—Vomiting—Epirubicin—liver cancer	1.87e-05	0.000303	CcSEcCtD
Sunitinib—Diarrhoea—Doxorubicin—liver cancer	1.86e-05	0.000302	CcSEcCtD
Sunitinib—Rash—Epirubicin—liver cancer	1.86e-05	0.0003	CcSEcCtD
Sunitinib—Dermatitis—Epirubicin—liver cancer	1.85e-05	0.0003	CcSEcCtD
Sunitinib—Headache—Epirubicin—liver cancer	1.84e-05	0.000298	CcSEcCtD
Sunitinib—Dizziness—Doxorubicin—liver cancer	1.8e-05	0.000291	CcSEcCtD
Sunitinib—Nausea—Epirubicin—liver cancer	1.75e-05	0.000283	CcSEcCtD
Sunitinib—Vomiting—Doxorubicin—liver cancer	1.73e-05	0.00028	CcSEcCtD
Sunitinib—Rash—Doxorubicin—liver cancer	1.72e-05	0.000278	CcSEcCtD
Sunitinib—Dermatitis—Doxorubicin—liver cancer	1.72e-05	0.000278	CcSEcCtD
Sunitinib—Headache—Doxorubicin—liver cancer	1.71e-05	0.000276	CcSEcCtD
Sunitinib—Nausea—Doxorubicin—liver cancer	1.62e-05	0.000262	CcSEcCtD
Sunitinib—FYN—Signaling Pathways—IL2—liver cancer	2.58e-07	2.78e-06	CbGpPWpGaD
Sunitinib—ABCB1—Metabolism—GSTM1—liver cancer	2.57e-07	2.78e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—CASP3—liver cancer	2.57e-07	2.77e-06	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—HPGDS—liver cancer	2.57e-07	2.77e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—IL2—liver cancer	2.56e-07	2.77e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling by GPCR—IL6—liver cancer	2.55e-07	2.75e-06	CbGpPWpGaD
Sunitinib—RPS6KB1—Signaling Pathways—HRAS—liver cancer	2.55e-07	2.75e-06	CbGpPWpGaD
Sunitinib—MAP2K5—Signaling Pathways—HRAS—liver cancer	2.55e-07	2.75e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling by GPCR—HRAS—liver cancer	2.55e-07	2.75e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Immune System—HRAS—liver cancer	2.54e-07	2.74e-06	CbGpPWpGaD
Sunitinib—YES1—Signaling Pathways—KRAS—liver cancer	2.54e-07	2.74e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Disease—PIK3CA—liver cancer	2.53e-07	2.74e-06	CbGpPWpGaD
Sunitinib—ROCK1—Signaling Pathways—IL6—liver cancer	2.53e-07	2.73e-06	CbGpPWpGaD
Sunitinib—CYP3A5—Metabolism—PIK3CG—liver cancer	2.53e-07	2.73e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—MMP9—liver cancer	2.53e-07	2.73e-06	CbGpPWpGaD
Sunitinib—FGFR1—Signaling Pathways—VEGFA—liver cancer	2.53e-07	2.73e-06	CbGpPWpGaD
Sunitinib—TYK2—Signaling Pathways—MYC—liver cancer	2.53e-07	2.73e-06	CbGpPWpGaD
Sunitinib—JAK2—Disease—KRAS—liver cancer	2.53e-07	2.73e-06	CbGpPWpGaD
Sunitinib—PDGFRA—Signaling Pathways—VEGFA—liver cancer	2.52e-07	2.72e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—MAPK8—liver cancer	2.52e-07	2.72e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—CDKN1A—liver cancer	2.52e-07	2.72e-06	CbGpPWpGaD
Sunitinib—TYK2—Signaling Pathways—TGFB1—liver cancer	2.52e-07	2.72e-06	CbGpPWpGaD
Sunitinib—JAK2—Immune System—PIK3CA—liver cancer	2.52e-07	2.72e-06	CbGpPWpGaD
Sunitinib—NTRK1—Signaling Pathways—IL6—liver cancer	2.52e-07	2.72e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling by GPCR—AKT1—liver cancer	2.52e-07	2.72e-06	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—CCND1—liver cancer	2.51e-07	2.71e-06	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—JUN—liver cancer	2.51e-07	2.71e-06	CbGpPWpGaD
Sunitinib—FGFR1—Signaling Pathways—STAT3—liver cancer	2.5e-07	2.7e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—CDKN1B—liver cancer	2.5e-07	2.7e-06	CbGpPWpGaD
Sunitinib—TYK2—Disease—AKT1—liver cancer	2.5e-07	2.7e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—CCND1—liver cancer	2.5e-07	2.7e-06	CbGpPWpGaD
Sunitinib—FGFR1—Disease—IL6—liver cancer	2.5e-07	2.7e-06	CbGpPWpGaD
Sunitinib—PDGFRA—Signaling Pathways—STAT3—liver cancer	2.5e-07	2.7e-06	CbGpPWpGaD
Sunitinib—FGFR2—Signaling Pathways—MYC—liver cancer	2.5e-07	2.69e-06	CbGpPWpGaD
Sunitinib—FGFR1—Immune System—AKT1—liver cancer	2.5e-07	2.69e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—JUN—liver cancer	2.49e-07	2.69e-06	CbGpPWpGaD
Sunitinib—PDGFRA—Disease—IL6—liver cancer	2.49e-07	2.69e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Immune System—IL6—liver cancer	2.49e-07	2.69e-06	CbGpPWpGaD
Sunitinib—FGFR2—Signaling Pathways—TGFB1—liver cancer	2.49e-07	2.69e-06	CbGpPWpGaD
Sunitinib—PDGFRA—Immune System—AKT1—liver cancer	2.49e-07	2.69e-06	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—CTNNB1—liver cancer	2.49e-07	2.69e-06	CbGpPWpGaD
Sunitinib—KDR—Signaling Pathways—HRAS—liver cancer	2.48e-07	2.68e-06	CbGpPWpGaD
Sunitinib—JAK2—GPCR downstream signaling—AKT1—liver cancer	2.48e-07	2.67e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—CTNNB1—liver cancer	2.47e-07	2.67e-06	CbGpPWpGaD
Sunitinib—FGFR2—Disease—AKT1—liver cancer	2.47e-07	2.67e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—MAPK8—liver cancer	2.46e-07	2.66e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—CASP3—liver cancer	2.45e-07	2.65e-06	CbGpPWpGaD
Sunitinib—MAP3K7—Signaling Pathways—MYC—liver cancer	2.45e-07	2.65e-06	CbGpPWpGaD
Sunitinib—KIT—Signaling Pathways—MYC—liver cancer	2.45e-07	2.65e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—IL2—liver cancer	2.45e-07	2.64e-06	CbGpPWpGaD
Sunitinib—FYN—Immune System—HRAS—liver cancer	2.45e-07	2.64e-06	CbGpPWpGaD
Sunitinib—MAP3K7—Signaling Pathways—TGFB1—liver cancer	2.45e-07	2.64e-06	CbGpPWpGaD
Sunitinib—KIT—Signaling Pathways—TGFB1—liver cancer	2.45e-07	2.64e-06	CbGpPWpGaD
Sunitinib—FYN—Disease—PIK3CA—liver cancer	2.44e-07	2.64e-06	CbGpPWpGaD
Sunitinib—CYP3A5—Metabolism—PPARG—liver cancer	2.44e-07	2.64e-06	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—MMP9—liver cancer	2.44e-07	2.63e-06	CbGpPWpGaD
Sunitinib—MAP2K5—Signaling Pathways—IL6—liver cancer	2.44e-07	2.63e-06	CbGpPWpGaD
Sunitinib—RPS6KB1—Signaling Pathways—IL6—liver cancer	2.44e-07	2.63e-06	CbGpPWpGaD
Sunitinib—ABCB1—Metabolism—CYP1A1—liver cancer	2.44e-07	2.63e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling by GPCR—IL6—liver cancer	2.44e-07	2.63e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Immune System—HRAS—liver cancer	2.44e-07	2.63e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Immune System—IL6—liver cancer	2.43e-07	2.62e-06	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—CDKN1A—liver cancer	2.43e-07	2.62e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Disease—PIK3CA—liver cancer	2.43e-07	2.62e-06	CbGpPWpGaD
Sunitinib—KIT—Disease—AKT1—liver cancer	2.43e-07	2.62e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—MMP9—liver cancer	2.43e-07	2.62e-06	CbGpPWpGaD
Sunitinib—PTK2B—Signaling Pathways—AKT1—liver cancer	2.42e-07	2.62e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—CDKN1A—liver cancer	2.42e-07	2.61e-06	CbGpPWpGaD
Sunitinib—IRAK1—Signaling Pathways—KRAS—liver cancer	2.41e-07	2.6e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Disease—HRAS—liver cancer	2.4e-07	2.59e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—CCND1—liver cancer	2.39e-07	2.58e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—JUN—liver cancer	2.38e-07	2.57e-06	CbGpPWpGaD
Sunitinib—KDR—Signaling Pathways—IL6—liver cancer	2.38e-07	2.57e-06	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—MAPK8—liver cancer	2.37e-07	2.56e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—CTNNB1—liver cancer	2.37e-07	2.55e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—MAPK8—liver cancer	2.36e-07	2.55e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling by GPCR—AKT1—liver cancer	2.35e-07	2.54e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Disease—HRAS—liver cancer	2.34e-07	2.53e-06	CbGpPWpGaD
Sunitinib—FYN—Immune System—IL6—liver cancer	2.34e-07	2.53e-06	CbGpPWpGaD
Sunitinib—TYK2—Signaling Pathways—KRAS—liver cancer	2.34e-07	2.52e-06	CbGpPWpGaD
Sunitinib—ROCK1—Signaling Pathways—AKT1—liver cancer	2.34e-07	2.52e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Immune System—IL6—liver cancer	2.33e-07	2.52e-06	CbGpPWpGaD
Sunitinib—YES1—Signaling Pathways—PIK3CA—liver cancer	2.33e-07	2.52e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—VEGFA—liver cancer	2.33e-07	2.51e-06	CbGpPWpGaD
Sunitinib—JAK2—Immune System—HRAS—liver cancer	2.33e-07	2.51e-06	CbGpPWpGaD
Sunitinib—FGFR1—Signaling Pathways—MYC—liver cancer	2.33e-07	2.51e-06	CbGpPWpGaD
Sunitinib—JAK2—Disease—PIK3CA—liver cancer	2.32e-07	2.51e-06	CbGpPWpGaD
Sunitinib—FGFR1—Signaling Pathways—TGFB1—liver cancer	2.32e-07	2.51e-06	CbGpPWpGaD
Sunitinib—PDGFRA—Signaling Pathways—MYC—liver cancer	2.32e-07	2.51e-06	CbGpPWpGaD
Sunitinib—NTRK1—Signaling Pathways—AKT1—liver cancer	2.32e-07	2.5e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—MMP9—liver cancer	2.32e-07	2.5e-06	CbGpPWpGaD
Sunitinib—PDGFRA—Signaling Pathways—TGFB1—liver cancer	2.32e-07	2.5e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—CDKN1A—liver cancer	2.31e-07	2.49e-06	CbGpPWpGaD
Sunitinib—FGFR2—Signaling Pathways—KRAS—liver cancer	2.31e-07	2.49e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—STAT3—liver cancer	2.31e-07	2.49e-06	CbGpPWpGaD
Sunitinib—FGFR1—Disease—AKT1—liver cancer	2.3e-07	2.49e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Disease—IL6—liver cancer	2.3e-07	2.48e-06	CbGpPWpGaD
Sunitinib—PDGFRA—Disease—AKT1—liver cancer	2.3e-07	2.48e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Immune System—AKT1—liver cancer	2.3e-07	2.48e-06	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—PSMA4—liver cancer	2.29e-07	2.47e-06	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—PSMD10—liver cancer	2.29e-07	2.47e-06	CbGpPWpGaD
Sunitinib—ABCB1—Metabolism—MTHFR—liver cancer	2.27e-07	2.45e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—VEGFA—liver cancer	2.27e-07	2.45e-06	CbGpPWpGaD
Sunitinib—MAP3K7—Signaling Pathways—KRAS—liver cancer	2.27e-07	2.45e-06	CbGpPWpGaD
Sunitinib—KIT—Signaling Pathways—KRAS—liver cancer	2.27e-07	2.45e-06	CbGpPWpGaD
Sunitinib—FYN—Disease—HRAS—liver cancer	2.26e-07	2.44e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—MAPK8—liver cancer	2.26e-07	2.43e-06	CbGpPWpGaD
Sunitinib—YES1—Signaling Pathways—TP53—liver cancer	2.25e-07	2.43e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—STAT3—liver cancer	2.25e-07	2.43e-06	CbGpPWpGaD
Sunitinib—RPS6KB1—Signaling Pathways—AKT1—liver cancer	2.25e-07	2.43e-06	CbGpPWpGaD
Sunitinib—MAP2K5—Signaling Pathways—AKT1—liver cancer	2.25e-07	2.43e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling by GPCR—AKT1—liver cancer	2.25e-07	2.43e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Disease—HRAS—liver cancer	2.25e-07	2.43e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Disease—IL6—liver cancer	2.24e-07	2.42e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Immune System—AKT1—liver cancer	2.24e-07	2.42e-06	CbGpPWpGaD
Sunitinib—ABCB1—Metabolism—PPARA—liver cancer	2.23e-07	2.41e-06	CbGpPWpGaD
Sunitinib—JAK2—Immune System—IL6—liver cancer	2.23e-07	2.4e-06	CbGpPWpGaD
Sunitinib—CYP3A5—Metabolism—PIK3CD—liver cancer	2.23e-07	2.4e-06	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—GOT2—liver cancer	2.22e-07	2.4e-06	CbGpPWpGaD
Sunitinib—IRAK1—Signaling Pathways—PIK3CA—liver cancer	2.21e-07	2.39e-06	CbGpPWpGaD
Sunitinib—CYP3A5—Metabolism—ALB—liver cancer	2.2e-07	2.37e-06	CbGpPWpGaD
Sunitinib—KDR—Signaling Pathways—AKT1—liver cancer	2.19e-07	2.37e-06	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—VEGFA—liver cancer	2.19e-07	2.36e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—VEGFA—liver cancer	2.18e-07	2.35e-06	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—STAT3—liver cancer	2.17e-07	2.34e-06	CbGpPWpGaD
Sunitinib—FYN—Disease—IL6—liver cancer	2.16e-07	2.34e-06	CbGpPWpGaD
Sunitinib—FYN—Immune System—AKT1—liver cancer	2.16e-07	2.33e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—STAT3—liver cancer	2.16e-07	2.33e-06	CbGpPWpGaD
Sunitinib—YES1—Signaling Pathways—HRAS—liver cancer	2.16e-07	2.33e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Disease—IL6—liver cancer	2.15e-07	2.32e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Immune System—AKT1—liver cancer	2.15e-07	2.32e-06	CbGpPWpGaD
Sunitinib—FGFR1—Signaling Pathways—KRAS—liver cancer	2.15e-07	2.32e-06	CbGpPWpGaD
Sunitinib—JAK2—Disease—HRAS—liver cancer	2.15e-07	2.32e-06	CbGpPWpGaD
Sunitinib—TYK2—Signaling Pathways—PIK3CA—liver cancer	2.15e-07	2.32e-06	CbGpPWpGaD
Sunitinib—PDGFRA—Signaling Pathways—KRAS—liver cancer	2.14e-07	2.31e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—MYC—liver cancer	2.14e-07	2.31e-06	CbGpPWpGaD
Sunitinib—IRAK1—Signaling Pathways—TP53—liver cancer	2.14e-07	2.31e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—TGFB1—liver cancer	2.14e-07	2.31e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Disease—AKT1—liver cancer	2.12e-07	2.29e-06	CbGpPWpGaD
Sunitinib—FGFR2—Signaling Pathways—PIK3CA—liver cancer	2.12e-07	2.29e-06	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—CYP2E1—liver cancer	2.09e-07	2.26e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—MYC—liver cancer	2.09e-07	2.26e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—TGFB1—liver cancer	2.09e-07	2.25e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—VEGFA—liver cancer	2.08e-07	2.25e-06	CbGpPWpGaD
Sunitinib—KIT—Signaling Pathways—PIK3CA—liver cancer	2.08e-07	2.25e-06	CbGpPWpGaD
Sunitinib—MAP3K7—Signaling Pathways—PIK3CA—liver cancer	2.08e-07	2.25e-06	CbGpPWpGaD
Sunitinib—TYK2—Signaling Pathways—TP53—liver cancer	2.08e-07	2.24e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Disease—AKT1—liver cancer	2.07e-07	2.24e-06	CbGpPWpGaD
Sunitinib—YES1—Signaling Pathways—IL6—liver cancer	2.06e-07	2.23e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—STAT3—liver cancer	2.06e-07	2.23e-06	CbGpPWpGaD
Sunitinib—JAK2—Disease—IL6—liver cancer	2.06e-07	2.22e-06	CbGpPWpGaD
Sunitinib—JAK2—Immune System—AKT1—liver cancer	2.05e-07	2.22e-06	CbGpPWpGaD
Sunitinib—FGFR2—Signaling Pathways—TP53—liver cancer	2.05e-07	2.21e-06	CbGpPWpGaD
Sunitinib—IRAK1—Signaling Pathways—HRAS—liver cancer	2.05e-07	2.21e-06	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—MYC—liver cancer	2.02e-07	2.18e-06	CbGpPWpGaD
Sunitinib—MAP3K7—Signaling Pathways—TP53—liver cancer	2.01e-07	2.17e-06	CbGpPWpGaD
Sunitinib—KIT—Signaling Pathways—TP53—liver cancer	2.01e-07	2.17e-06	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—TGFB1—liver cancer	2.01e-07	2.17e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—MYC—liver cancer	2e-07	2.16e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—TGFB1—liver cancer	2e-07	2.16e-06	CbGpPWpGaD
Sunitinib—FYN—Disease—AKT1—liver cancer	2e-07	2.15e-06	CbGpPWpGaD
Sunitinib—TYK2—Signaling Pathways—HRAS—liver cancer	1.99e-07	2.14e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Disease—AKT1—liver cancer	1.99e-07	2.14e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—KRAS—liver cancer	1.98e-07	2.14e-06	CbGpPWpGaD
Sunitinib—FGFR1—Signaling Pathways—PIK3CA—liver cancer	1.98e-07	2.13e-06	CbGpPWpGaD
Sunitinib—PDGFRA—Signaling Pathways—PIK3CA—liver cancer	1.97e-07	2.13e-06	CbGpPWpGaD
Sunitinib—FGFR2—Signaling Pathways—HRAS—liver cancer	1.96e-07	2.12e-06	CbGpPWpGaD
Sunitinib—IRAK1—Signaling Pathways—IL6—liver cancer	1.96e-07	2.11e-06	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—CYCS—liver cancer	1.96e-07	2.11e-06	CbGpPWpGaD
Sunitinib—CYP3A5—Metabolism—PIK3CB—liver cancer	1.94e-07	2.09e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—KRAS—liver cancer	1.93e-07	2.09e-06	CbGpPWpGaD
Sunitinib—MAP3K7—Signaling Pathways—HRAS—liver cancer	1.93e-07	2.08e-06	CbGpPWpGaD
Sunitinib—KIT—Signaling Pathways—HRAS—liver cancer	1.93e-07	2.08e-06	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—GOT1—liver cancer	1.92e-07	2.07e-06	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—GGT1—liver cancer	1.92e-07	2.07e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—MYC—liver cancer	1.92e-07	2.07e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—TGFB1—liver cancer	1.91e-07	2.06e-06	CbGpPWpGaD
Sunitinib—FGFR1—Signaling Pathways—TP53—liver cancer	1.91e-07	2.06e-06	CbGpPWpGaD
Sunitinib—ABCB1—Metabolism—PIK3CG—liver cancer	1.91e-07	2.06e-06	CbGpPWpGaD
Sunitinib—PDGFRA—Signaling Pathways—TP53—liver cancer	1.91e-07	2.06e-06	CbGpPWpGaD
Sunitinib—YES1—Signaling Pathways—AKT1—liver cancer	1.9e-07	2.06e-06	CbGpPWpGaD
Sunitinib—TYK2—Signaling Pathways—IL6—liver cancer	1.9e-07	2.05e-06	CbGpPWpGaD
Sunitinib—JAK2—Disease—AKT1—liver cancer	1.9e-07	2.05e-06	CbGpPWpGaD
Sunitinib—FGFR2—Signaling Pathways—IL6—liver cancer	1.88e-07	2.03e-06	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—KRAS—liver cancer	1.86e-07	2.01e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—KRAS—liver cancer	1.85e-07	2e-06	CbGpPWpGaD
Sunitinib—ABCB1—Metabolism—PPARG—liver cancer	1.84e-07	1.99e-06	CbGpPWpGaD
Sunitinib—MAP3K7—Signaling Pathways—IL6—liver cancer	1.84e-07	1.99e-06	CbGpPWpGaD
Sunitinib—KIT—Signaling Pathways—IL6—liver cancer	1.84e-07	1.99e-06	CbGpPWpGaD
Sunitinib—FGFR1—Signaling Pathways—HRAS—liver cancer	1.83e-07	1.97e-06	CbGpPWpGaD
Sunitinib—PDGFRA—Signaling Pathways—HRAS—liver cancer	1.82e-07	1.97e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—PIK3CA—liver cancer	1.82e-07	1.96e-06	CbGpPWpGaD
Sunitinib—IRAK1—Signaling Pathways—AKT1—liver cancer	1.81e-07	1.95e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—PIK3CA—liver cancer	1.77e-07	1.92e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—KRAS—liver cancer	1.77e-07	1.91e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—TP53—liver cancer	1.76e-07	1.9e-06	CbGpPWpGaD
Sunitinib—TYK2—Signaling Pathways—AKT1—liver cancer	1.75e-07	1.89e-06	CbGpPWpGaD
Sunitinib—FGFR1—Signaling Pathways—IL6—liver cancer	1.75e-07	1.89e-06	CbGpPWpGaD
Sunitinib—PDGFRA—Signaling Pathways—IL6—liver cancer	1.74e-07	1.88e-06	CbGpPWpGaD
Sunitinib—FGFR2—Signaling Pathways—AKT1—liver cancer	1.73e-07	1.87e-06	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—GSTP1—liver cancer	1.72e-07	1.86e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—TP53—liver cancer	1.72e-07	1.85e-06	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—PIK3CA—liver cancer	1.71e-07	1.85e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—PIK3CA—liver cancer	1.7e-07	1.84e-06	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—HMOX1—liver cancer	1.7e-07	1.84e-06	CbGpPWpGaD
Sunitinib—MAP3K7—Signaling Pathways—AKT1—liver cancer	1.7e-07	1.84e-06	CbGpPWpGaD
Sunitinib—KIT—Signaling Pathways—AKT1—liver cancer	1.7e-07	1.84e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—HRAS—liver cancer	1.68e-07	1.82e-06	CbGpPWpGaD
Sunitinib—ABCB1—Metabolism—PIK3CD—liver cancer	1.68e-07	1.81e-06	CbGpPWpGaD
Sunitinib—ABCB1—Metabolism—ALB—liver cancer	1.66e-07	1.79e-06	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—TP53—liver cancer	1.66e-07	1.79e-06	CbGpPWpGaD
Sunitinib—ABCG2—Metabolism—PIK3CA—liver cancer	1.65e-07	1.78e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—TP53—liver cancer	1.65e-07	1.78e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—HRAS—liver cancer	1.64e-07	1.77e-06	CbGpPWpGaD
Sunitinib—CYP3A7—Metabolism—PIK3CA—liver cancer	1.64e-07	1.77e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—PIK3CA—liver cancer	1.63e-07	1.76e-06	CbGpPWpGaD
Sunitinib—FGFR1—Signaling Pathways—AKT1—liver cancer	1.61e-07	1.74e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—IL6—liver cancer	1.61e-07	1.74e-06	CbGpPWpGaD
Sunitinib—PDGFRA—Signaling Pathways—AKT1—liver cancer	1.61e-07	1.74e-06	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—GSTM1—liver cancer	1.58e-07	1.71e-06	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—HRAS—liver cancer	1.58e-07	1.71e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—HRAS—liver cancer	1.57e-07	1.7e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—TP53—liver cancer	1.57e-07	1.7e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—IL6—liver cancer	1.57e-07	1.7e-06	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—IL6—liver cancer	1.51e-07	1.64e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—IL6—liver cancer	1.51e-07	1.63e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—HRAS—liver cancer	1.5e-07	1.62e-06	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—CYP1A1—liver cancer	1.5e-07	1.62e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—AKT1—liver cancer	1.49e-07	1.6e-06	CbGpPWpGaD
Sunitinib—ABCB1—Metabolism—PIK3CB—liver cancer	1.46e-07	1.58e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—AKT1—liver cancer	1.45e-07	1.57e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—IL6—liver cancer	1.44e-07	1.55e-06	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—MTHFR—liver cancer	1.4e-07	1.51e-06	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—AKT1—liver cancer	1.4e-07	1.51e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—AKT1—liver cancer	1.39e-07	1.5e-06	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—PPARA—liver cancer	1.37e-07	1.48e-06	CbGpPWpGaD
Sunitinib—ABCG2—Metabolism—AKT1—liver cancer	1.35e-07	1.46e-06	CbGpPWpGaD
Sunitinib—CYP3A7—Metabolism—AKT1—liver cancer	1.34e-07	1.44e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—AKT1—liver cancer	1.33e-07	1.43e-06	CbGpPWpGaD
Sunitinib—CYP3A5—Metabolism—PIK3CA—liver cancer	1.18e-07	1.28e-06	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—PIK3CG—liver cancer	1.18e-07	1.27e-06	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—PPARG—liver cancer	1.14e-07	1.23e-06	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—PIK3CD—liver cancer	1.03e-07	1.12e-06	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—ALB—liver cancer	1.02e-07	1.1e-06	CbGpPWpGaD
Sunitinib—CYP3A5—Metabolism—AKT1—liver cancer	9.66e-08	1.04e-06	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—PIK3CB—liver cancer	9.02e-08	9.73e-07	CbGpPWpGaD
Sunitinib—ABCB1—Metabolism—PIK3CA—liver cancer	8.92e-08	9.63e-07	CbGpPWpGaD
Sunitinib—ABCB1—Metabolism—AKT1—liver cancer	7.29e-08	7.87e-07	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—PIK3CA—liver cancer	5.5e-08	5.93e-07	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—AKT1—liver cancer	4.49e-08	4.85e-07	CbGpPWpGaD
